After more than 20 years of development, lentiviral hematopoietic stem cell gene therapy has entered the stage of initial clinical implementation for immune deficiencies and storage disorders. This brief review summarizes the development and applications, focusing on the lysosomal enzyme deficiencies, especially Pompe disease.
Get full access to this article
View all access options for this article.
References
1.
AiutiA., CassaniB., AndolfiG., et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Invest., 117, 2233–2240.
2.
BaumC., von KalleC., StaalF.J., et al. (2004). Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther., 9, 5–13.
3.
BiascoL., AmbrosiA., PellinD., et al. (2011). Integration profile of retroviralvector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol. Med., 3, 89–101.
BraunC.J., BoztugK., ParuzynskiA., et al. (2014). Gene therapy for Wiskott-Aldrichsyndrome—long-term efficacy and genotoxicity. Sci. Transl. Med., 6, 227ra33.
6.
CartierN., Hacein-Bey-AbinaS., BartholomaeC.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326, 818–823.
7.
CesanaD., RanzaniM., VolpinM., et al. (2014). Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol. Ther., 22, 774–785.
8.
ChenJ., LarochelleA., FrickerS., et al. (2006). Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood, 107, 3764–3771.
9.
DeichmannA., Hacein-Bey-AbinaS., SchmidtM., et al. (2007). Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest., 117, 2225–2232.
10.
DeichmannA., BrugmanM.H., BartholomaeC.C., et al. (2011). Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol. Ther., 19, 2031–2039.
11.
EnquistI.B., NilssonE., OokaA., et al. (2006). Effective cell and gene therapy in a murine model of Gaucher disease. Proc. Natl. Acad. Sci. USA, 103, 13819–13824.
12.
FullerM., Van der PloegA., ReuserA.J., et al. (1995). Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase. Eur. J. Biochem., 234, 903–909.
13.
GasparH.B., ParsleyK.L., HoweS., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet, 364, 2181–2187.
14.
GenoveseP., SchiroliG., EscobarG., et al. (2014). Targeted genome editing in human repopulating haematopoietic stem cells. Nature, 510, 235–240.
15.
GentnerB., VisigalliI., HiramatsuH., et al. (2010). Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci. Transl. Med., 2, 58ra84.
16.
Hacein-Bey-AbinaS., HauerJ., LimA., et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 363, 355–364.
17.
HoogerbruggeP.M., WagemakerG., van BekkumD.W., et al. (1986). Bone marrow transplantation for Pompé's disease. N. Engl. J. Med., 315, 65–66.
18.
HoogerbruggeP.M., SuzukiK., SuzukiK., et al. (1988). Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science, 239, 1035–1038.
19.
KustikovaO.S., GeigerH., LiZ., et al. (2007). Retroviral vector insertion sites associated with dominant hematopoietic clones mark “stemness”. pathways. Blood, 109, 1897–1907.
20.
NaldiniL., BlömerU., GallayP., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272, 263–267.
21.
Pike-OverzetK., de RidderD., WeerkampF., et al. (2006). Gene therapy: is IL2RG oncogenic in T-cell development?. Nature, 443, E5; discussion E6–E7.
22.
Pike-OverzetK., van der BurgM., WagemakerG., et al. (2007). New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol. Ther., 15, 1910–1916.
23.
PompeJ.C. (1932). Over idiopathische hypertrofie van het hart. Ned. Tijdschr. Geneeskd., 76, 304–311.
24.
RochaV., WagnerJ.E.Jr., SobocinskiK.A., et al. (2000). Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N. Engl. J. Med., 342, 1846–1854.
25.
SchambachA., BohneJ., BaumC., et al. (2006). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther., 13, 641–645.
26.
SchwarzwaelderK., HoweS.J., SchmidtM., et al. (2007). Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest., 117, 2241–2249.
27.
ShouY., MaZ., LuT., and SorrentinoB.P. (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. USA, 103, 11730–11735.
28.
van den HoutH.M., HopW., van DiggelenO.P., et al. (2003). The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics, 112, 332–340.
29.
van der PloegA.T., and ReuserA.J. (2008). Pompe's disease. Lancet, 372, 1342–1353.
30.
van GelderC.M., Hoogeveen-WesterveldM., KroosM.A., et al. (2014). Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J. Inherit. Metab. Dis. [Epub ahead of print]
31.
van TilN.P., StokM., Aerts KayaF.S., et al. (2010). Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood, 115, 5329–5337.
32.
van TilN.P., and WagemakerG. (2014). Lentiviral gene transduction of mouse and human hematopoietic stem cells. Methods Mol. Biol., 1185, 311–319.
33.
VisigalliI., DelaiS., PolitiL.S., et al. (2010). Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood, 116, 5130–5139.
34.
WaliaJ.S., NeschadimA., Lopez-PerezO., et al. (2011). Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Hum. Gene Ther., 22, 679–687.
35.
YoshimitsuM., HiguchiK., RamsubirS., et al. (2007). Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther., 14, 256–265.
36.
ZhangF., ThornhillS.I., HoweS.J., et al. (2007). Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood, 110, 1448–1457.
